



RXVET
PHARMACEUTICALS



Osphos®

For the alleviation of clinical forelimb lameness associated with the bone resorptive processes of the navicular bone in adult horses.

Osphos® combats excessive bone resorption. The Bisphosphonate Clodronic acid helps to restore the balance between resorption and remodelling in diseased bone. It binds to hydroxyapatite crystals on the navicular bone which are taken in by the osteoclast during bone resorption. This inhibits osteoclast activity by preventing them from adhering to the bone surface and inducing osteoclast cell death and helps to reduce mineral loss.

Osphos® is administered by simple intramuscular injection and should be evenly spread over 2 to 3 injection sites.

ACVM Registration No: A11391

Osphos® Features:

- 🐎 **Simple administration.** A full dose can be administered in minutes.
- 🐎 **Well tolerated** in clinical trials. Side effects are mild and transient.
- 🐎 **Proven efficacy.** Clinical improvement in lameness visible at 28 days after treatment.

What dose to use?

Osphos® is presented in a 15 ml vial sufficient to treat one horse.

Recommended dosage:

🐎 3 ml per 100 kg of bodyweight

Solution for injection:

🐎 Disodium Clodronate 60 mg/ml as Clodronic acid 51 mg/ml

For more information please contact your Veterinary Account Manager or RXVET Technical Support Line on 0800 4 RXVET (79838)

RXVET Limited | 0800 4 RXVET | info@rxvet.co.nz | www.rxvet.co.nz